Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Contact
Bahnhofstrasse 20
Zug6300
CHET: +41 417119325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.70 | 48.80 | 0.56% |
| CAC 40 | 7,900.03 | 21.57 | 0.27% |
| DAX 40 | 24,465.96 | 83.60 | -0.34% |
| Dow JONES (US) | 44,714.68 | 256.38 | 0.58% |
| FTSE 100 | 8,975.60 | 108.58 | 1.22% |
| HKSE | 24,028.37 | 136.05 | 0.57% |
| NASDAQ | 20,579.80 | 31.53 | -0.15% |
| Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
| NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
| S&P 500 | 6,274.47 | 11.21 | 0.18% |
| S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
| SSE Composite Index | 3,509.68 | 16.63 | 0.48% |